Literature DB >> 2543709

Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients.

S W Chou1.   

Abstract

Analysis of cytomegalovirus (CMV) isolates shed by 51 recipients of organs from 24 CMV-seropositive donors was used to assess the relative characteristics of primary infection, reactivation of endogenous virus, and reinfection by a donor CMV strain. Reinfection was more frequent than reactivation of endogenous virus. Symptomatic CMV disease was identified in 21 of 25 primary infections, 2 of 16 reinfections, and 1 of 4 cases of endogenous reactivation. Before receiving a transplant, reinfected recipients had detectable neutralizing antibody to the specific reinfecting strain of CMV and to laboratory strain AD169. Following reinfection, rises in neutralizing antibody titers were observed, comparable to the responses of those with reactivation of endogenous CMV. The preexisting level of neutralizing antibody did not appear to predict clinical outcome, and moderately high levels of neutralizing antibody did not prevent viremia. Thus, posttransplant CMV reinfection occurs frequently and appears clinically, serologically, and virologically similar to reactivation of endogenous virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543709     DOI: 10.1093/infdis/160.1.16

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates.

Authors:  Lucy Rasmussen; Aimee Geissler; Catherine Cowan; Amanda Chase; Mark Winters
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 2.  Antimicrobial strategies in the care of organ transplant recipients.

Authors:  R H Rubin; N E Tolkoff-Rubin
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

3.  Strain-specific neutralization of human cytomegalovirus isolates by human sera.

Authors:  M Klein; K Schoppel; N Amvrossiadis; M Mach
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

4.  Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation.

Authors:  G J Boland; R J Hene; C Ververs; M A de Haan; G C de Gast
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

Review 5.  Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens.

Authors:  B Weber; W Braun; J Cinatl; H W Doerr
Journal:  Clin Investig       Date:  1993-04

Review 6.  Cytomegalovirus infection and disease after liver transplantation. An overview.

Authors:  R J Stratta; M S Shaeffer; R S Markin; R P Wood; A N Langnas; E C Reed; J P Donovan; G L Woods; K A Bradshaw; T J Pillen
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

7.  Association between cytomegalovirus antibody levels and cognitive functioning in non-elderly adults.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Lucy A B Schweinfurth; Christina L G Savage; Robert Yolken
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

Review 8.  Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update.

Authors:  Katya Prakash; Aditya Chandorkar; Kapil K Saharia
Journal:  Diagnostics (Basel)       Date:  2021-05-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.